FDA Approves Varithena For Treating Varicose Veins

BTG plc Nov. 26 announced that the Food and Drug Administration has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein system, otherwise known as varicose veins.

Varithena (formerly known as Varisolve PEM) is a pharmaceutical-grade, low-nitrogen, polidocanol foam dispensed from a proprietary canister device, the United Kingdom-based company said.

Current treatments for varicose veins include thermal ablation and surgery, BTG said. Varithena provides U.S. physicians with the only FDA-approved comprehensive therapy to improve symptoms and the appearance of a wide range of varicose veins.

Varithena treatment is ...